Treatment of urinary tract infections due to Pseudomonas aeruginosa with cefsulodin. 1984

H A Elder, and I Roy

Effectiveness of cefsulodin in the treatment of urinary tract infections due to Pseudomonas aeruginosa was evaluated by means of a comparative study with 123 enrolled patients. Seventy-four patients whose therapy could be evaluated were randomly assigned to therapy with either cefsulodin at various dosages or an aminoglycoside (gentamicin, tobramycin, or amikacin). In all cases, the treatment course was five to 10 days (mean, 7.4 days), and levels of cefsulodin in the serum of patients administered the lowest dose (250 mg every 6 hr) exceeded the 90% minimal inhibitory concentration (MIC90) of cefsulodin for P. aeruginosa. Cefsulodin therapy cleared P. aeruginosa from 37 of 50 patients, and therapy with an aminoglycoside cleared P. aeruginosa from 16 of 24 patients. The rate of clearance was unrelated to the antibiotic used (cefsulodin, gentamicin, tobramycin, or amikacin) or to whether patients were catheterized, the infectious agent was resistant to carbenicillin or gentamicin or to 4 micrograms of cefsulodin/ml, or the level of cefsulodin in serum regularly exceeded the minimal bactericidal concentration (MBC) for the infecting strain. The mean MIC and MBC for strains isolated from patients who experienced relapse (failure) were not higher than the mean MIC and MBC for strains cleared by cefsulodin.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002441 Cefsulodin A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients. Abbott 46811,CGP-7174-E,Cefsulodin Monosodium Salt,Cefsulodin Sodium,Monaspor,Pyocefal,SCE-129,CGP 7174 E,CGP7174E,Monosodium Salt, Cefsulodin,SCE 129,SCE129,Sodium, Cefsulodin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin

Related Publications

H A Elder, and I Roy
January 1986, The Journal of international medical research,
H A Elder, and I Roy
January 1984, Reviews of infectious diseases,
H A Elder, and I Roy
May 1984, The Journal of antimicrobial chemotherapy,
H A Elder, and I Roy
April 1967, The Journal of antibiotics. Ser. B,
H A Elder, and I Roy
June 1967, The Journal of antibiotics. Ser. B,
H A Elder, and I Roy
January 1984, Reviews of infectious diseases,
H A Elder, and I Roy
October 1998, Journal of tropical pediatrics,
H A Elder, and I Roy
November 1971, Giornale di malattie infettive e parassitarie,
H A Elder, and I Roy
October 1982, JAMA,
Copied contents to your clipboard!